Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5911)
All Articles published online
|
Publishing Process of This Article
|
May 26, 2014 (publication date) through Oct 2, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Biological Chemistry
ISSN
1949-8454
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sun XX, Dai MS. Deubiquitinating enzyme regulation of the p53 pathway: A lesson from Otub1. World J Biol Chem 2014; 5(2): 75-84 [PMID: 24920999 DOI: 10.4331/wjbc.v5.i2.75] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8454/full/v5/i2/75.htm |
| Number | Citing Articles |
| 1 |
Yanming Wu, Sa’udah Badriah Mohd Sani, Ke Peng, Tao Lin, Chenghao Tan, Xufeng Huang, Zhengrui Li. Research progress of the Otubains subfamily in hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2024; 179: 117348 doi: 10.1016/j.biopha.2024.117348
|
| 2 |
Jie‐Lei Zhang, Bin‐Bin Du, Dian‐Hong Zhang, Huan Li, Ling‐Yao Kong, Guang‐Jian Fan, Ya‐Peng Li, Peng‐Cheng Li, Cui Liang, Zheng Wang, Lu‐Lu Yang, Zheng‐Yang Hao, Lei‐Ming Wu, Zhen Huang, Jian‐Zeng Dong, Jin‐Ying Zhang, Rui Yao, Shou‐Jun Wang, Yan‐Zhou Zhang. OTUB1 alleviates NASH through inhibition of the TRAF6‐ASK1 signaling pathways. Hepatology 2022; 75(5): 1218 doi: 10.1002/hep.32179
|
| 3 |
Chrisanta Harakandi, Lauraine Nininahazwe, Haiwei Xu, Bingrui Liu, Chenghua He, Yi-Chao Zheng, Hang Zhang. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy. Bioorganic Chemistry 2021; 116: 105273 doi: 10.1016/j.bioorg.2021.105273
|
| 4 |
Sofia Ferrer, Michael E. Muratore, Peter Buijnsters. The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 2013. Expert Opinion on Therapeutic Patents 2022; 32(5): 523 doi: 10.1080/13543776.2022.2003780
|
| 5 |
Ju-Bin Kang, Murad-Ali Shah, Dong-Ju Park, Phil-Ok Koh. Retinoic acid regulates the ubiquitin–proteasome system in a middle cerebral artery occlusion animal model. Laboratory Animal Research 2022; 38(1) doi: 10.1186/s42826-022-00123-6
|
| 6 |
May-Britt Firnau, Angela Brieger. CK2 and the Hallmarks of Cancer. Biomedicines 2022; 10(8): 1987 doi: 10.3390/biomedicines10081987
|
| 7 |
Christopher L. Brooks. Encyclopedia of Cell Biology. 2023; : 327 doi: 10.1016/B978-0-12-821618-7.00251-0
|
| 8 |
Xing Wang, Yuanyuan Liu, Qiuyan Zhao, Xin Wang, Xinyi Chen, Li Hou, Shaodan Tian, Zi-Mei Peng, Xiao-Jian Han, Tao Wang, Zhen Zhang, Fang-Fang Tou, Shan Huang, Jun Rao, Lixiao Chen, Zhi Zheng. PILRB potentiates the PI3K/AKT signaling pathway and reprograms cholesterol metabolism to drive gastric tumorigenesis and metastasis. Cell Death & Disease 2024; 15(9) doi: 10.1038/s41419-024-07026-5
|
| 9 |
Xing Liu, Hongyan Deng, Jinhua Tang, Zixuan Wang, Chunchun Zhu, Xiaolian Cai, Fangjing Rong, Xiaoyun Chen, Xueyi Sun, Shuke Jia, Gang Ouyang, Wenhua Li, Wuhan Xiao. OTUB1 augments hypoxia signaling via its non-canonical ubiquitination inhibition of HIF-1α during hypoxia adaptation. Cell Death & Disease 2022; 13(6) doi: 10.1038/s41419-022-05008-z
|
| 10 |
Lucas Cruz, Paula Soares, Marcelo Correia. Ubiquitin-Specific Proteases: Players in Cancer Cellular Processes. Pharmaceuticals 2021; 14(9): 848 doi: 10.3390/ph14090848
|